Trial NCT00251433

View at ClinicalTrials.gov 
Org. Study IDs: EGF100161
Secondary IDs: 2005-000846-35 CLAP016A2101

Last trial update was posted on 2023-03-31

MeSH Interventions

Docetaxel Lapatinib Trastuzumab

MeSH Conditions

Breast Neoplasms

Other Conditions

Neoplasms, Breast

Stopping Reasons

EGF100161 (NCT00251433) was terminated in Phase I (Phase II expansion portion of the study was never initiated) by sponsor decision.

Limitations And Caveats

N/A

Result Publications


Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID